Press Releases

Date Title and Summary Additional Formats
Toggle Summary Biocept Informs Stockholders of Key Dates and Terms Related to Announced Rights Offering
SAN DIEGO , July 11, 2018 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC) (" Biocept "), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, today provided an
View HTML
Toggle Summary Biocept Highlights Recent Progress and Outlines Near-Term Strategic Priorities in CEO Letter to Stockholders
SAN DIEGO , June 25, 2018 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that President and CEO Michael W.
View HTML
Toggle Summary Published Case Report Demonstrates the Clinical Utility of Biocept's CTC Platform in the Management of Patients with Metastatic Breast Cancer
Peer-reviewed article in journal Clinics in Oncology highlights ability of Biocept's Target Selector™ to detect a key biomarker to qualify breast cancer patients for targeted therapy when tissue biopsy is inconclusive SAN DIEGO , June 18, 2018 /PRNewswire/ --  Biocept, Inc.
View HTML
Toggle Summary VWR, Part of Avantor, and Biocept Announce the Launch of CEE-Sure Blood Collection Tubes for cfDNA and CTCs
Biocept's patented collection tubes now available from VWR for the safe transport of patient specimens containing both circulating cell-free DNA (cfDNA) and circulating tumor cells (CTCs) at room temperature SAN DIEGO , June 11, 2018 /PRNewswire/ --  Biocept, Inc .
View HTML
Toggle Summary Biocept to Present at the 8th Annual LD Micro Invitational Conference on June 5
SAN DIEGO , May 29, 2018 /PRNewswire/ --  Biocept, Inc.  (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable information to physicians to improve cancer treatment, announces that President and CEO Michael
View HTML
Toggle Summary Biocept Reports First Quarter 2018 Financial Results
Company to host conference call at 4:30 p.m. Eastern time today SAN DIEGO , May 15, 2018 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer
View HTML
Toggle Summary Biocept to Release First Quarter 2018 Financial Results and Host Investor Conference Call on May 15, 2018
SAN DIEGO , May 8, 2018 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable  information to physicians to improve cancer treatment, announces that it will release financial
View HTML
Toggle Summary Case Report in Journal of Thoracic Oncology Demonstrates the Clinical Utility of Biocept's Liquid Biopsy Test for Patient Diagnosed with Non-Small Cell Lung Cancer
Letter to the editor highlights capability of Target Selector™ test to detect ROS1, a lung cancer biomarker used to qualify patients for targeted therapies that can improve treatment outcomes SAN DIEGO , May 1, 2018 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of
View HTML
Toggle Summary Published Case Study Demonstrates the Clinical Utility of Biocept's Liquid Biopsy Test for ALK Rearrangements
Peer-reviewed article in Oncology & Hematology Review highlights capability of Target Selector™ to detect a key biomarker to qualify lung cancer patients for targeted therapy when tissue biopsy is inadequate SAN DIEGO , April 27, 2018 /PRNewswire/ --  Biocept, Inc.
View HTML
Toggle Summary Biocept to Webcast Presentation at the 7th Annual MicroCap Conference
Company to also co-host roundtable discussion SAN DIEGO , April 6, 2018 /PRNewswire/ --  Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with
View HTML